血液和脑脊液中中枢神经系统淋巴瘤的诊断标志物:一项系统综述
该系统综述检索血液或脑脊液标志物诊断中枢神经系统淋巴瘤的研究,纳入25项研究,用QUADAS-2评估方法学质量,评价18种脑脊液标志物和3种血液标志物的诊断价值。所有研究偏倚风险较高,15项研究适用性存疑;CXCL-13、β2微球蛋白和新蝶呤诊断潜力最高,但用于临床实践前仍需进一步研究。
要点
- 所有纳入研究偏倚风险较高,15项研究适用性存疑。
- CXCL-13、β2微球蛋白和新蝶呤诊断中枢神经系统淋巴瘤的潜力最高。
- 上述标志物用于临床实践前仍需进一步研究。
核心结论
- CXCL-13、β2微球蛋白和新蝶呤诊断中枢神经系统淋巴瘤的潜力最高,但用于临床实践前仍需进一步研究。
研究设计与样本
- 系统文献检索血液或脑脊液标志物诊断中枢神经系统淋巴瘤的研究,用QUADAS-2评估方法学质量,纳入25项研究。
主要发现
- 纳入研究报告18种脑脊液标志物(microRNA-21、-19b、-92a、RNU2-1f、CXCL13、白细胞介素-6、-8、-10、可溶性白细胞介素-2受体、可溶性CD19、可溶性CD27、肿瘤坏死因子-α、β2微球蛋白、抗凝血酶III、可溶性跨膜激活剂及钙调亲环素配体相互作用分子、可溶性B细胞成熟抗原、新蝶呤、骨桥蛋白)和3种血液标志物(microRNA-21、可溶性CD27、β2微球蛋白)的诊断价值。
- 所有研究偏倚风险较高,15项研究适用性存疑。
关键数值与推荐
- 评价标志物在给定阈值下的诊断价值,以及患者组与对照组均值或中位数水平的差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所有研究偏倚风险较高。
- 15项研究适用性存疑。
- CXCL-13、β2微球蛋白和新蝶呤用于临床实践前仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosing central nervous system (CNS) lymphoma remains a challenge. Most patients have to undergo brain biopsy to obtain tissue for diagnosis, with associated risks of serious complications. Diagnostic markers in blood or cerebrospinal fluid (CSF) could facilitate early diagnosis with low complication rates. We performed a systematic literature search for studies on markers in blood or cerebrospinal fluid for the diagnosis CNS lymphoma and assessed the methodological quality of studies with the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2). We evaluated diagnostic value of the markers at a given threshold, as well as differences between mean or median levels in patients versus control groups. Twenty-five studies were included, reporting diagnostic value for 18 markers in CSF (microRNAs -21, -19b, and -92a, RNU2-1f, CXCL13, interleukins -6, -8, and -10, soluble interleukin-2-receptor, soluble CD19, soluble CD27, tumour necrosis factor-alfa, beta-2-microglobulin, antithrombin III, soluble transmembrane activator and calcium modulator and cyclophilin ligand interactor, soluble B cell maturation antigen, neopterin and osteopontin) and three markers in blood (microRNA-21 soluble CD27, and beta-2-microglobulin). All studies were at considerable risk of bias and there were concerns regarding the applicability of 15 studies. CXCL-13, beta-2-microglobulin and neopterin have the highest potential in diagnosing CNS lymphoma, but further study is still needed before they can be used in clinical practice.
引用
- van Westrhenen A, Smidt LCA, Seute T, et al. Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review. Br J Haematol. 2018. PMID: 29808930. doi:10.1111/bjh.15410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。